Rite Aid exhibited more of the same in its fiscal second quarter. Net revenue fell 2.7% to $6.3 billion, and net losses landed at $116 million. That's significantly better than the $222 million that Rite Aid lost in the same quarter a year ago, although large impairment and debt retirement charges hampered last year's results. This year, the company cut its SG&A costs, but it still suffered from massive interest payments on the mountain of debt it took on to buy Eckerd and Brooks in 2007. Rite Aid's liabilities outweigh its assets, giving the company a negative book value.
A host of problems
Walgreen and CVS are doing much better than Rite Aid; both are actually making money. Furthermore, Wal-Mart
So in addition to intense competition and a recession, these cuts are essentially making health care more expensive for everyone, right down to the end user. Rite Aid may be the worst off right now, but no one is immune.
A grave situation
Even worse for shareholders, Rite Aid lowered its full-year revenue and earnings guidance in light of these challenges. But keep in mind that to some extent, all retail pharmacies are seeing the same pressures. With unemployment still relatively high, people will continue to seek out bargains, put off refilling their prescriptions, and generally spend less at the drugstore. If this situation doesn't improve, it could signal dark days ahead -- not only for retail pharmacies, but also for consumers, drug companies, and the entire health-care system.
You should avoid Rite Aid like the plague for now. And if its problems are a sign of things to come, other health-care stocks may not be far behind.
Have a different view? Share it in the comments section below.
The Fool owns shares of Costco, which is a Motley Fool Stock Advisor recommendation. Costco and Wal-Mart are Motley Fool Inside Value recommendations. Try any of our Foolish newsletter services free for 30 days.
Fool contributor Chris Jones owns shares of CVS, but he doesn't own shares of any other company mentioned in this article. Nor is he short anything. The Motley Fool's disclosure policy already got its flu shots.